NASDAQ:HRMY

Harmony Biosciences Holdings Stock News

etoro logo Buy HRMY
*Your capital is at risk
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) fo
Harmony Biosciences (HRMY) possesses solid growth attributes, which could help it handily outperform the market.
The average of price targets set by Wall Street analysts indicates a potential upside of 27% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable,
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two companies is
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 2
New York State Common Retirement Fund increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) by 43.9% in the undefined quarter, according to its most recent disclosure with the Se
AI fears and U.S.-Iran tensions rattle markets. Value investors should consider buying stocks like HRMY, AGRO, SQM, ANGI and PHIN.
Low P/B screen spotlights IVZ, HRMY, CNXC, PAX and GPN as undervalued picks with solid growth potential heading into 2026.
Sandip Kapadia sold 3,746 shares directly for a total transaction value of approximately $139,171 on Jan. 26, 2026. Kapadia had sold all of his shares in Harmony Biosciences earlier in January, but hi
Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue
Sandip Kapadia sold 20,961 shares for a transaction value of approximately $752,800 on Jan. 15, 2026. Harmony Biosciences reported strong Q3 2025 earnings and expects to generate $1 billion in revenue
Tech turmoil weighs on Wall Street, but CNXC, GPN, HRMY, and UHS stand out with low P/CF ratios and solid growth.
Four GARP stocks - including NEXA - pair discounted PEG ratios with strong growth potential, showing how value and growth can work together.
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE